MX2023007308A - Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t. - Google Patents

Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t.

Info

Publication number
MX2023007308A
MX2023007308A MX2023007308A MX2023007308A MX2023007308A MX 2023007308 A MX2023007308 A MX 2023007308A MX 2023007308 A MX2023007308 A MX 2023007308A MX 2023007308 A MX2023007308 A MX 2023007308A MX 2023007308 A MX2023007308 A MX 2023007308A
Authority
MX
Mexico
Prior art keywords
variable domains
single variable
polypeptides
immunoglobulin single
cell receptor
Prior art date
Application number
MX2023007308A
Other languages
English (en)
Inventor
Hoorick Diane Van
Carlo Boutton
Daniel Janssen
Evelyne Dombrecht
Bram Laukens
Paolo Meoni
Lily Pao
Jan Pype
Peter Schotte
Benedikte Serruys
Ana Paula Vintem
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2023007308A publication Critical patent/MX2023007308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente tecnología tiene como objetivo proporcionar un tipo novedoso de fármaco para tratar sujeto que padece cáncer. Específicamente, la tecnología proporciona polipéptidos que comprenden al menos cuatro dominios variables únicos de inmunoglobulina (ISVD), caracterizados porque un ISVD se une a TCR y al menos dos ISVD se unen a GPC3. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones.
MX2023007308A 2020-12-18 2021-12-17 Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t. MX2023007308A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127224P 2020-12-18 2020-12-18
EP20306633 2020-12-21
PCT/EP2021/086559 WO2022129560A1 (en) 2020-12-18 2021-12-17 Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor

Publications (1)

Publication Number Publication Date
MX2023007308A true MX2023007308A (es) 2023-07-04

Family

ID=79283159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007308A MX2023007308A (es) 2020-12-18 2021-12-17 Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t.

Country Status (11)

Country Link
US (1) US11932702B2 (es)
EP (1) EP4262985A1 (es)
JP (1) JP2023553697A (es)
KR (1) KR20230123495A (es)
AU (1) AU2021399955A1 (es)
CA (1) CA3205422A1 (es)
CO (1) CO2023009231A2 (es)
IL (1) IL303783A (es)
MX (1) MX2023007308A (es)
TW (1) TW202241947A (es)
WO (1) WO2022129560A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350074B (es) * 2011-06-23 2017-08-25 Ablynx Nv Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.
US20240109965A1 (en) * 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
WO2024118866A1 (en) * 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
EP2314317A3 (en) 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
ATE537188T1 (de) 2005-05-18 2011-12-15 Ablynx Nv Serumalbuminbindende proteine
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US8680247B2 (en) 2007-07-17 2014-03-25 Medarex, L.L.C. Monoclonal antibodies against glypican-3
JP6087054B2 (ja) 2009-12-25 2017-03-01 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
MX350074B (es) 2011-06-23 2017-08-25 Ablynx Nv Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
RS60717B1 (sr) 2014-05-16 2020-09-30 Ablynx Nv Varijabilni domeni imunoglobulina
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3294768B1 (en) 2015-05-13 2019-08-21 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
CN108290943A (zh) 2015-11-13 2018-07-17 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
US11332519B2 (en) 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
KR20180116215A (ko) * 2016-03-14 2018-10-24 추가이 세이야쿠 가부시키가이샤 암의 치료에 이용하기 위한 세포상해 유도 치료제
BR112019010061A2 (pt) * 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Immunoglobulin sites with a single variable enhance serum albumin binding
BR112019014599A2 (pt) 2017-01-17 2020-03-03 Ablynx N.V. Ligantes de albumina sérica melhorados
JP7300385B2 (ja) 2017-01-17 2023-06-29 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤

Also Published As

Publication number Publication date
CO2023009231A2 (es) 2023-07-21
US20220213215A1 (en) 2022-07-07
US11932702B2 (en) 2024-03-19
IL303783A (en) 2023-08-01
TW202241947A (zh) 2022-11-01
WO2022129560A1 (en) 2022-06-23
EP4262985A1 (en) 2023-10-25
AU2021399955A1 (en) 2023-08-03
KR20230123495A (ko) 2023-08-23
CA3205422A1 (en) 2022-06-23
JP2023553697A (ja) 2023-12-25

Similar Documents

Publication Publication Date Title
MX2023007308A (es) Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t.
Yu et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Yi et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Rafiq et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Qin et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
MX2022006881A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
WO2018187613A3 (en) Anti-icos agonist antibodies and uses thereof
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
Freund et al. Targeting endogenous nuclear antigens by electrotransfer of monoclonal antibodies in living cells
AU2019343184A8 (en) Compositions and methods for treating cancer with anti-CD123 immunotherapy
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
Alvarez-Cienfuegos et al. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
Mølgaard et al. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies
MX2022006880A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
Qasemi et al. Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell
Di Luca et al. Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment
MX2023003522A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
Chen et al. A direct interaction between P53-binding protein 1 and minichromosome maintenance complex in Hepg2 cells
EP4378485A3 (en) Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
Min et al. Cytoplasmic HMGB1 and HMGB1-Beclin1 complex are increased in radioresistant oral squamous cell carcinoma
Lu et al. Regulatory effects of IRF4 on immune cells in the tumor microenvironment
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.